NTRK alterations (NTRK1/2/3) were present in 0.9% and 0.5%, ROS1 alterations in 0.4% and 0.2%, RET alterations in 0.6% and 0.4%, and ALK alterations in 0.5% and 0.4% of samples in colon and rectal cancer, respectively (Fig. S2B,D). This evidence concerns the gene ROS1 and rectal cancer.